Gufic Biosciences Limited · NSE:GUFICBIO
Gufic Biosciences — Q1 FY2027 Earnings Presentation
36 slides from Gufic Biosciences's earnings presentation
Slide 1: Delivering Care & Cure Investor Presentation
Delivering Care & Cure Investor Presentation For Q1FY2027
Slide 2: Safe Harbor
Safe Harbor This presen tation has be en prepare d by an d is the sole responsibility of Gufic Biosci ences Li mited (the “Company” ). By accessing this presen tation, you ar e agreeing to be bound by the trailing restrictions. This presen tation do es not constitute or for m part of any of fer or i
Slide 3: Q1 FY27 Business & Financial Highlights
Q1 FY27 Business & Financial Highlights
Slide 4: Indore Facility update: The Manufacturing Platform
Indore Facility update: The Manufacturing Platform We have built one of the most advanced lyophilized Timeline of our phased approach injectable facilities, commenced production in Milestone Target Status & Commentary October 2024 Installation & Operational ✅ Completed – facility meets WHO GMP, EU G
Slide 5: Indore Plant: The Journey So Far
Indore Plant: The Journey So Far Gufic Advantage What We Delivered Quarter by Quarter Fully Integrated Injectable Platform Quarter Milestone Detail / Evidence Barrier Why It Matters Q4 FY25 Commercial production Oct 2024 first batch; plant capitalized Q3 FY25 One of the largest Indian companies that
Slide 6: I. Hospital Injectable Platform
I. Hospital Injectable Platform. Therapy Focus: Anti-Microbials, Immunology & Cardiac Critical Care A. Critical Care Cluster B. Sparsh Hospital-first execution to widen ICU account coverage and compound molecule- Scaling a hospital + nursing-home platform by tightening execution infrastructure and c
Slide 7: Complex injectable pipeline for the hospital platform
Complex injectable pipeline for the hospital platform Drug Class Unique Advantages Complexity in Manufacturing Domestic Business Breakup Novel β-lactam/β- Targets multi-drug resistant Gram-negative Complex formulation with dual agents requires precise lactamase Inhibitor bacteria; highly effective f
Slide 8: II. Women's Health Platform
II. Women’s Health Platform. Therapy Focus: Assisted Reproductive Technology(IVF), Immunology & Ortho-gynae A. Ferticare Cluster B. Zenova Scaling a high-science fertility franchise by owning Reproductive Immunology and Upgrading portfolio quality by scaling prescription-led power brands, expanding
Slide 9: III. Botulinum Toxin Platform
III. Botulinum Toxin Platform. Therapy Focus: Aesthetics & Neurology A. Aesthaderm B. Neurocare Scaling from a toxin brand into a full-stack aesthetics platform by widening Scaling the Therapeutic Toxin Franchise by creating new injectors in guideline- injector creation, strengthening evidence, and
Slide 10: IV. Nutra, Ayurveda & Others
IV. Nutra, Ayurveda & Others. Therapy Focus: Chronic Musculoskeletal Pain & Gastro Nutra, Ayurveda & Others Repositioning the portfolio as a science-led chronic-care platform in pain, arthritis and GI—driving sustainable reach through differentiated formulations and next-gen prescriber ecosystem bui
Slide 11: V. International Business
V. International Business: Shifting international growth from opportunistic filings to an IP-owned, complex- injectables-led export & licensing engine. Strategy: Why We Changed the Model Regulatory update for Q1 FY2027 Gufic's international business historically was a distributor-led, opportunistic-
Slide 12: VI. Near Term Indore Scale Up Plan
VI. Near Term Indore Scale Up Plan: Converting complex injectables expertise into a global sales and licensing engine. RA Status--> Key Products with Stringent Countries-Ready Dossiers Strategic Roadmap (3–5 Years) Regulated Market Current Market Size Market Share Goal: Capture 5–10% in identified
Slide 13: Gufic's R&D Focus
Gufic’s R&D Focus: Peptides & Critical API Self-Reliance Novel Drug Delivery Systems (NDDS) Clinical Programs 13
Slide 14: Research & Development
Research & Development C. API Development — Reducing Supply Chain Dependence A. Peptides & Critical API Self-Reliance API Category Strategic Goal Gufic is building in-house peptide API development capability — Develop in-house to reduce Chinese dependence for reducing dependence on Chinese API suppl
Slide 15: Research & Development: Clinical Programs
Research & Development Clinical Programs — 17 Active/Pipeline Studies Phase Count Therapy Areas Reproductive immunology (Guficin Alpha/RIF), Botulinum Toxin Ongoing Clinical 5 (Aesthaderm), Gonadotropin (Puregraf), Wound healing, Phase III Trials biosimilar (rFSH ) Pipeline Clinical NDDS formats, wo
Slide 16: Strategic Initiatives
Strategic Initiatives Strategic Initiatives that will further amplify growth over the next few years Increase in overall market and market share in Leverage new biological Botulinum Toxin range of Increase market share in technology platform to products through Commercialization of contract manufact
Slide 17: Profit & Loss Statement
Profit & Loss Statement Particulars Q1 FY27 Q4 FY26 Q1 FY26 FY26 FY25 (in Rs. Crore) Total Revenue 260.8 252.1 226.9 940.5 819.8 EBITDA 47.2 44.7 33.2 152.9 138.6 EBITDA Margin % 18.09% 17.74% 14.60% 16.26% 16.91% Profit before Tax 30.1 27.6 16.3 85.5 94.4 PBT Margins % 11.56% 10.96% 7.1% 9.09% 11.5
Slide 18: Company Overview
Company Overview
Slide 19: About Gufic Biosciences
About Gufic Biosciences Research based Pharmaceutical Company recognized for its innovative, high quality Pharmaceuticals Nutraceuticals, Natural Herbal products One of the Largest Manufacturers of Lyophilized Injections in India with a wide range of products in various therapy areas BUSINESS STRUCT
Slide 20: World Class Manufacturing Infrastructure
World Class Manufacturing Infrastructure Unit - I at Navsari Unit - II at Navsari Gufic - Belgaum Botulinum Toxin Facility Lyophilized Injectables Facility Natural Products Facility Lyophilized/Powder Injectables Facility Capability to manufacture Liposomal Natural Products (Topical/Liquid) Amphoter
Slide 21: New Manufacturing Infrastructure
New Manufacturing Infrastructure Unit - III at Indore Penem Block UPDATE ON INDORE Indore Lyophilized/Powder Injectables Dedicated facility for Penem Commercial Production Achieved Facility Carbapenems (Lyophilized / Dry Capability to cater to regulated Powder Inj / Oral Solids / Dual markets such a
Slide 22: Botulinum Toxin Facility
Botulinum Toxin Facility Gufic has built a state-of-the-art manufacturing facility for Botulinum Toxin in Navsari Gufic has partnered with Prime Bio, USA for manufacturing Botulinum Toxin API and formulation Gufic is equipped with all the necessary analytical testing procedures for safety and effica
Slide 23: Consolidating the Domestic Branded Business
Consolidating the Domestic Branded Business Products CRITICAL CARE INFERTILITY MASS SPECIALITY 100+ SKU’s Field Force: 250 Field Force: >150 Field Force: >180 200+ Therapy Areas: Antibacterial, Therapy Areas: Hormones, Therapy Areas: Anti Infectives, Antifungal, Pain Management, Recombinant Products
Slide 24: Expanding Creditability in CMO Business
Expanding Creditability in CMO Business Offer CMO services for India and 70+ 150+ Products Reliable CMO service for quality products over a Global Markets Companies across multiple therapy areas decade One of the Largest Supplier of Formulations Liposomal Doxycycline Tigecycline Gonadotropins Micafu
Slide 25: Expanding Geographical Reach
Expanding Geographical Reach 130+ Products registered globally (in 15+ countries) 150+ Products in pipeline for registration (in 30+ countries) CANADA | COSTA RICA | PANAMA | COLUMBIA | CHILE | LATVIA | LITHUANIA | BELARUS | GERMANY | AUSTRIA | PORTUGAL | MOROCCO ALGERIA | DOMINICAN REPUBLIC | VENEZ
Slide 26: Building API Capabilities
Building API Capabilities Special Facility dedicated to API Focused on developing non The categories of API’s infringing, novel, cost manufactured are effective and scalable antifungals, antibacterial, chemical process for APIs, anesthetics and Peptides and Cyclopeptides intermediates for antifungal
Slide 27: Strong Partnership & Licensing Deals
Strong Partnership & Licensing Deals Through our collaborations with global partners that are European leader in IV drug researching to expand the frontiers of pharma and delivery systems. Collaborated biotechnology, Gufic will be a technology bridge to the with Gufic to launch Dual future of health
Slide 28: Extensive Sales, Distribution IT Infrastructure in India
Extensive Sales, Distribution IT Infrastructure in India 2 Central Warehouses Pan India Presence with a located in North Delhi and field force of 1,000+ West Bhiwandi IT Infrastructure Retail coverage of more than 23 Carrying & Forwarding (C&F) agents across India Integrated IT Systems with Sales 1,
Slide 29: Growth Levers
Growth Levers 1 2 3 INTERNATIONAL INDIA BUSINESS CMO BUSINESS BUSINESS • Consolidation of the Critical Care Infertility • Expand our presence in regulated • Scale up the manufacturing capacity business markets such as US EU • Entry into new therapy areas Dermatology - • Consolidation of the clients
Slide 30: Our Robust R&D and Clinical team to augment growth
Our Robust R&D and Clinical team to augment growth Research & Development (R&D) Clinical Team State-of-the-art R&D Facility in Navsari, Gujarat with expertise in Formulation Development Technology Transfer API Development Patents in various therapy areas Granted: 5 Filed/In-process of filling : 8 Ma
Slide 31: Historical Financials
Historical Financials
Slide 32: Historical Financials
Historical Financials Particulars (Rs. Crs.) FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 Total Income 943.1 823.4 808.8 693.2 782.3 491.4 384.6 359.5 EBITDA 152.9 138.6 149.5 137.2 151.1 87.7 57.9 56.7 EBITDA Margin % 16.21% 16.83% 18.48% 19.79% 19.31% 17.85% 15.05% 15.77% Profit before Tax 85.5 94.4 11
Slide 33: Historical Balance Sheet (Equity & Liabilities)
Historical Balance Sheet (Equity & Liabilities) EQUITY & LIABILITIES (Rs. Crs.) Mar-26 Mar-25 Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Equity Share Capital 10 10 10 9.7 9.7 9.7 9.7 7.8 Other Equity 654.2 591.3 522.5 338.1 259.4 163.7 119.6 67.6 Total Equity 664.2 601.3 532.5 347.8 269.1 173.4 129.3
Slide 34: Historical Balance Sheet (Assets)
Historical Balance Sheet (Assets) ASSETS (Rs. Crs.) Mar-26 Mar-25 Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Non-Current Assets Property, plant and equipment 467.1 475.2 138.3 126.8 105.5 93.8 72.7 70.3 Intangible assets 6.2 6.3 5.6 0.7 0.6 0.4 0.6 0.4 Capital work-in-progress 22.1 21.8 307.1 169.6 4
Slide 35: Historical Cash Flows
Historical Cash Flows Cash Flow Statement (Rs. Crs.) FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 Net Profit Before Tax 85.5 94.4 115.7 106.7 126.9 57.7 30.1 35.3 Adjustments for: Non - Cash Items / Other Investment or 65.2 43.8 34.1 29.6 23.2 30.8 24.7 13.4 Financial Items Operating profit before workin
Slide 36: Thank You
THANK YOU Company: Gufic Biosciences Limited CIN: L24100MH1984PLC033519 Mr. Avik Das – Investor Relations avik.das@guficbio.com Tel: +91 22 67261000